SEC Form 4 · accession 0000950138-17-000016
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael-Bryant Hicks
Officer — General Counsel
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 8:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 3, 2017 | A | 4,833 | $0.00 | A | 7,943 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F2 | $51.73 | Jan 3, 2017 | A | 27,151 | A | Jan 3, 2018 | Jan 3, 2027 | Ordinary Shares | 27,151 | 27,151 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018.
- F2The options vest in four equal annual installments beginning January 3, 2018.